Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Leprosy with spontaneous type 1 lepra reaction as an initial cutaneous manifestation: a case from Japan.

Noda M, Tsunemi Y, Masui Y, Yoshizaki A, Ohmatsu H, Takazawa Y, Ishii N.

Eur J Dermatol. 2018 Dec 1;28(6):843-844. doi: 10.1684/ejd.2018.3428. No abstract available.

PMID:
30563805
2.

Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer.

Taira T, Yoh K, Nagase S, Kubota K, Ohmatsu H, Niho S, Onozawa M, Akimoto T, Ohe Y, Goto K.

Cancer Chemother Pharmacol. 2018 Mar;81(3):565-572. doi: 10.1007/s00280-018-3530-y. Epub 2018 Jan 31.

PMID:
29387962
3.

Efficacy of Cell-Free and Concentrated Ascites Reinfusion Therapy for Palliative Care in a Patient with Malignant Pleural Mesothelioma: A Case Report.

Hisakane K, Ohmatsu H, Umemura S, Kirita K, Matsumoto S, Yoh K, Niho S, Goto K.

J Nippon Med Sch. 2017;84(5):231-236. doi: 10.1272/jnms.84.231.

4.

Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.

Niho S, Ohe Y, Ohmatsu H, Umemura S, Matsumoto S, Yoh K, Goto K.

Lung Cancer. 2017 Jun;108:66-71. doi: 10.1016/j.lungcan.2017.02.018. Epub 2017 Mar 1.

PMID:
28625650
5.

IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.

Ohmatsu H, Humme D, Gonzalez J, Gulati N, Möbs M, Sterry W, Krueger JG.

Oncoimmunology. 2016 May 5;6(2):e1181237. doi: 10.1080/2162402X.2016.1181237. eCollection 2017.

6.

Prognostic Factor Analysis in Patients With Small-Cell Lung Cancer Treated With Third-Line Chemotherapy.

Saruwatari K, Umemura S, Nomura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Ohe Y, Goto K.

Clin Lung Cancer. 2016 Nov;17(6):581-587. doi: 10.1016/j.cllc.2016.05.022. Epub 2016 Jun 16.

PMID:
27424806
7.

Changes in the tumor microenvironment during lymphatic metastasis of lung squamous cell carcinoma.

Ikemura S, Aramaki N, Fujii S, Kirita K, Umemura S, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Kuwata T, Kojima M, Ochiai A, Betsuyaku T, Tsuboi M, Goto K, Ishii G.

Cancer Sci. 2017 Jan;108(1):136-142. doi: 10.1111/cas.13110. Epub 2017 Jan 21.

8.

Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.

Zenke Y, Umemura S, Sugiyama E, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Goto K.

Lung Cancer. 2016 Sep;99:1-3. doi: 10.1016/j.lungcan.2016.05.002. Epub 2016 Jun 6.

PMID:
27565905
9.

Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung.

Miyoshi T, Umemura S, Matsumura Y, Mimaki S, Tada S, Makinoshima H, Ishii G, Udagawa H, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Aokage K, Hishida T, Yoshida J, Nagai K, Goto K, Tsuboi M, Tsuchihara K.

Clin Cancer Res. 2017 Feb 1;23(3):757-765. doi: 10.1158/1078-0432.CCR-16-0355. Epub 2016 Aug 9.

10.

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.

Yoh K, Doi T, Ohmatsu H, Kojima T, Takahashi H, Zenke Y, Wacheck V, Enatsu S, Nakamura T, Turner K, Uenaka K.

Invest New Drugs. 2016 Oct;34(5):584-95. doi: 10.1007/s10637-016-0370-7. Epub 2016 Sep 1.

11.

Discrimination of Dysplastic Nevi from Common Melanocytic Nevi by Cellular and Molecular Criteria.

Mitsui H, Kiecker F, Shemer A, Cannizzaro MV, Wang CQF, Gulati N, Ohmatsu H, Shah KR, Gilleaudeau P, Sullivan-Whalen M, Cueto I, McNutt NS, Suárez-Fariñas M, Krueger JG.

J Invest Dermatol. 2016 Oct;136(10):2030-2040. doi: 10.1016/j.jid.2015.11.035. Epub 2016 Jul 1.

12.

A CASE OF UNILATERAL RETINAL PIGMENT EPITHELIUM DYSGENESIS.

Yamasaki A, Tominaga T, Ishikura R, Ohmatsu H, Inoue Y.

Retin Cases Brief Rep. 2017 Spring;11(2):156-159. doi: 10.1097/ICB.0000000000000317.

PMID:
27124794
13.

Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non-Small Cell Lung Cancer.

Zenke Y, Umemura S, Motegi A, Furukawa K, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Akimoto T, Goto K.

J Thorac Oncol. 2016 Jul;11(7):1181-3. doi: 10.1016/j.jtho.2016.04.011. Epub 2016 Apr 22. No abstract available.

14.

Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study.

Kakinuma R, Noguchi M, Ashizawa K, Kuriyama K, Maeshima AM, Koizumi N, Kondo T, Matsuguma H, Nitta N, Ohmatsu H, Okami J, Suehisa H, Yamaji T, Kodama K, Mori K, Yamada K, Matsuno Y, Murayama S, Murata K.

J Thorac Oncol. 2016 Jul;11(7):1012-28. doi: 10.1016/j.jtho.2016.04.006. Epub 2016 Apr 16.

15.

Factors influencing the concordance of histological subtype diagnosis from biopsy and resected specimens of lung adenocarcinoma.

Matsuzawa R, Kirita K, Kuwata T, Umemura S, Matsumoto S, Fujii S, Yoh K, Kojima M, Niho S, Ohmatsu H, Ochiai A, Tsuboi M, Goto K, Ishii G.

Lung Cancer. 2016 Apr;94:1-6. doi: 10.1016/j.lungcan.2016.01.009. Epub 2016 Jan 22.

PMID:
26973199
16.

Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.

Zenke Y, Yoh K, Matsumoto S, Umemura S, Niho S, Ohmatsu H, Goto K, Ohe Y.

Clin Lung Cancer. 2016 Sep;17(5):412-418. doi: 10.1016/j.cllc.2016.01.006. Epub 2016 Feb 5.

PMID:
26944770
18.

Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.

Saruwatari K, Ikemura S, Sekihara K, Kuwata T, Fujii S, Umemura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Ochiai A, Kohrogi H, Tsuboi M, Goto K, Ishii G.

Lung Cancer. 2016 Jan;91:7-14. doi: 10.1016/j.lungcan.2015.11.012. Epub 2015 Nov 15.

PMID:
26711928
19.

RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.

Yoshida T, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y, Goto K.

Lung Cancer. 2015 Dec;90(3):477-83. doi: 10.1016/j.lungcan.2015.09.025. Epub 2015 Oct 9.

PMID:
26604031
20.

Unique intravascular tumor microenvironment predicting recurrence of lung squamous cell carcinoma.

Hisakane K, Saruwatari K, Fujii S, Kirita K, Umemura S, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Kuwata T, Ochiai A, Gemma A, Tsuboi M, Goto K, Ishii G.

J Cancer Res Clin Oncol. 2016 Mar;142(3):593-600. doi: 10.1007/s00432-015-2068-1. Epub 2015 Oct 31.

PMID:
26521256
21.

Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.

Sugiyama E, Umemura S, Nomura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Ohe Y, Goto K.

Lung Cancer. 2015 Nov;90(2):307-13. doi: 10.1016/j.lungcan.2015.08.004. Epub 2015 Aug 12.

PMID:
26323212
22.

Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.

Asao T, Nokihara H, Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Yamamoto N, Sekine I, Kunitoh H, Fujiwara Y, Ohe Y.

Jpn J Clin Oncol. 2015 Oct;45(10):941-6. doi: 10.1093/jjco/hyv107. Epub 2015 Jul 31.

PMID:
26232449
23.

Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia.

Watanabe N, Niho S, Kirita K, Umemura S, Matsumoto S, Yoh K, Ohmatsu H, Goto K.

Cancer Chemother Pharmacol. 2015 Jul;76(1):69-74. doi: 10.1007/s00280-015-2775-y. Epub 2015 May 15.

PMID:
25976217
24.

Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth.

Takahashi A, Ishii G, Neri S, Yoshida T, Hashimoto H, Suzuki S, Umemura S, Matsumoto S, Yoh K, Niho S, Goto K, Ohmatsu H, Nagai K, Gemma A, Ohe Y, Ochiai A.

Oncotarget. 2015 Apr 20;6(11):9531-41.

25.

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.

Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S; Tokyo Cooperative Oncology Group.

Ann Oncol. 2015 Jul;26(7):1401-8. doi: 10.1093/annonc/mdv190. Epub 2015 Apr 23.

26.

Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target.

Humme D, Haider A, Möbs M, Mitsui H, Suárez-Fariñas M, Ohmatsu H, Isabell Geilen C, Eberle J, Krueger JG, Beyer M, Hummel M, Anagnostopoulos I, Sterry W, Assaf C.

J Invest Dermatol. 2015 Sep;135(9):2292-2300. doi: 10.1038/jid.2015.139. Epub 2015 Apr 7.

27.

Docetaxel for platinum-refractory advanced thymic carcinoma.

Watanabe N, Umemura S, Niho S, Kirita K, Matsumoto S, Yoh K, Ohmatsu H, Goto K.

Jpn J Clin Oncol. 2015 Jul;45(7):665-9. doi: 10.1093/jjco/hyv046. Epub 2015 Apr 2.

PMID:
25840444
28.

CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis.

Sugaya M, Morimura S, Suga H, Kawaguchi M, Miyagaki T, Ohmatsu H, Fujita H, Sato S.

J Dermatol. 2015 Jun;42(6):613-5. doi: 10.1111/1346-8138.12852. Epub 2015 Mar 26.

PMID:
25809616
29.

Vinorelbine and cisplatin in patients with advanced non-small cell lung cancer with interstitial pneumonia.

Watanabe N, Niho S, Kirita K, Umemura S, Matsumoto S, Yoh K, Ohmatsu H, Goto K.

Anticancer Res. 2015 Mar;35(3):1697-701.

PMID:
25750330
30.

Comparison of the expression levels of molecular markers among the peripheral area and central area of primary tumor and metastatic lymph node tumor in patients with squamous cell carcinoma of the lung.

Udagawa H, Ishii G, Morise M, Umemura S, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Goto K, Ochiai A, Ohe Y.

J Cancer Res Clin Oncol. 2015 Aug;141(8):1417-25. doi: 10.1007/s00432-015-1912-7. Epub 2015 Jan 9.

PMID:
25573625
31.

Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy.

Koriyama H, Ishii G, Yoh K, Neri S, Morise M, Umemura S, Matsumoto S, Niho S, Ohmatsu H, Tsuboi M, Goto K, Ochiai A.

J Cancer Res Clin Oncol. 2015 Jul;141(7):1163-70. doi: 10.1007/s00432-014-1891-0. Epub 2014 Dec 2.

PMID:
25446816
32.

Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.

Yoshida T, Ishii G, Goto K, Neri S, Hashimoto H, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Iida S, Niimi A, Nagai K, Ohe Y, Ochiai A.

Clin Cancer Res. 2015 Feb 1;21(3):642-51. doi: 10.1158/1078-0432.CCR-14-0846. Epub 2014 Nov 11.

33.

TOX expression in different subtypes of cutaneous lymphoma.

Morimura S, Sugaya M, Suga H, Miyagaki T, Ohmatsu H, Fujita H, Asano Y, Tada Y, Kadono T, Sato S.

Arch Dermatol Res. 2014 Nov;306(9):843-9. doi: 10.1007/s00403-014-1501-7. Epub 2014 Sep 13.

PMID:
25216799
34.

Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.

Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H, Niho S, Yoh K, Matsumoto S, Takahashi A, Morise M, Nakamura Y, Ochiai A, Nagai K, Iwakawa R, Kohno T, Yokota J, Ohe Y, Esumi H, Tsuchihara K, Goto K.

J Thorac Oncol. 2014 Sep;9(9):1324-31. doi: 10.1097/JTO.0000000000000250.

35.

Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.

Morise M, Niho S, Umemura S, Matsumoto S, Yoh K, Goto K, Ohmatsu H, Ohe Y.

Jpn J Clin Oncol. 2014 Sep;44(9):846-51. doi: 10.1093/jjco/hyu094. Epub 2014 Jul 23.

PMID:
25057092
36.

IL32 is progressively expressed in mycosis fungoides independent of helper T-cell 2 and helper T-cell 9 polarization.

Ohmatsu H, Humme D, Gulati N, Gonzalez J, Möbs M, Suárez-Fariñas M, Cardinale I, Mitsui H, Guttman-Yassky E, Sterry W, Krueger JG.

Cancer Immunol Res. 2014 Sep;2(9):890-900. doi: 10.1158/2326-6066.CIR-13-0199-T. Epub 2014 Jun 17.

37.

Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous T-cell lymphoma.

Suga H, Sugaya M, Miyagaki T, Ohmatsu H, Kawaguchi M, Takahashi N, Fujita H, Asano Y, Tada Y, Kadono T, Sato S.

Clin Cancer Res. 2014 Aug 15;20(16):4339-48. doi: 10.1158/1078-0432.CCR-14-0077. Epub 2014 Jun 11.

38.

Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.

Yoshida T, Niho S, Toda M, Goto K, Yoh K, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y.

Jpn J Clin Oncol. 2014 Apr;44(4):346-54. doi: 10.1093/jjco/hyu004. Epub 2014 Feb 5.

PMID:
24503028
39.

Primary cutaneous γδ T-cell lymphoma following mycosis fungoides.

Suga H, Sugaya M, Miyagaki T, Ohmatsu H, Fujita H, Sato S.

Int J Dermatol. 2014 Feb;53(2):e82-4. doi: 10.1111/j.1365-4632.2012.05494.x. No abstract available.

PMID:
24444029
40.

Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin in Japanese Patients With Locally Advanced Nonsquamous Non-Small Cell Lung Cancer: A Post Hoc Analysis of Survival and Recurrent Sites.

Niho S, Nokihara H, Nihei K, Akimoto T, Sumi M, Ito Y, Yoh K, Goto K, Ohmatsu H, Horinouchi H, Yamamoto N, Sekine I, Kubota K, Ohe Y, Tamura T.

Am J Clin Oncol. 2016 Apr;39(2):132-5. doi: 10.1097/COC.0000000000000030.

PMID:
24441582
41.

Serum autotaxin levels correlate with pruritus in patients with atopic dermatitis.

Nakao M, Sugaya M, Suga H, Kawaguchi M, Morimura S, Kai H, Ohmatsu H, Fujita H, Asano Y, Tada Y, Kadono T, Sato S.

J Invest Dermatol. 2014 Jun;134(6):1745-1747. doi: 10.1038/jid.2014.24. Epub 2014 Jan 17. No abstract available. Erratum in: J Invest Dermatol. 2016 Sep;136(9):1925.

42.

Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: identification of prognostic microenvironmental factors after chemoradiation.

Zenke Y, Ishii G, Ohe Y, Kaseda K, Yoshida T, Matsumoto S, Umemura S, Yoh K, Niho S, Goto K, Ohmatsu H, Kuwata T, Nagai K, Ochiai A.

Pathol Int. 2013 Dec;63(12):599-606. doi: 10.1111/pin.12122.

PMID:
24422956
43.

Identification of biological properties of intralymphatic tumor related to the development of lymph node metastasis in lung adenocarcinoma.

Kirita K, Ishii G, Matsuwaki R, Matsumura Y, Umemura S, Matsumoto S, Yoh K, Niho S, Goto K, Ohmatsu H, Ohe Y, Nagai K, Ochiai A.

PLoS One. 2013 Dec 23;8(12):e83537. doi: 10.1371/journal.pone.0083537. eCollection 2013.

44.

A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.

Sekine I, Okamoto H, Horai T, Nakagawa K, Ohmatsu H, Yokoyama A, Katakami N, Shibuya M, Saijo N, Fukuoka M.

Clin Lung Cancer. 2014 Mar;15(2):96-102. doi: 10.1016/j.cllc.2013.11.006. Epub 2013 Nov 14.

PMID:
24361248
45.

Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine carcinomas of the lung.

Takahashi A, Ishii G, Kinoshita T, Yoshida T, Umemura S, Hishida T, Yoh K, Niho S, Goto K, Ohmatsu H, Ohe Y, Nagai K, Ochiai A.

J Cancer Res Clin Oncol. 2013 Nov;139(11):1869-78. doi: 10.1007/s00432-013-1502-5. Epub 2013 Sep 7.

PMID:
24013219
46.

Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma.

Suga H, Sugaya M, Miyagaki T, Kawaguchi M, Morimura S, Kai H, Kagami S, Ohmatsu H, Fujita H, Asano Y, Tada Y, Kadono T, Sato S.

Eur J Dermatol. 2013 Sep-Oct;23(5):629-35. doi: 10.1684/ejd.2013.2107.

PMID:
24001451
47.

Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.

Yoshida T, Ishii G, Goto K, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Nagai K, Ohe Y, Ochiai A.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1691-700. doi: 10.1007/s00432-013-1495-0. Epub 2013 Aug 22.

PMID:
23974272
48.

Peripheral T cell lymphoma, not otherwise specified, showing multiple ulcers on the extremities.

Suga H, Sugaya M, Yamamoto M, Miyagaki T, Ohmatsu H, Hoashi T, Sato S.

Int J Dermatol. 2013 Sep;52(9):1147-9. doi: 10.1111/j.1365-4632.2011.05187.x. No abstract available.

PMID:
23962266
49.

Reagents inducing epidermal proliferation also induce pigmentation: induction of keratinocyte proliferation as a novel strategy for the treatment of vitiligo.

Wu CS, Komine M, Fujimoto S, Ohmatsu H, Kikuchi K, Tada Y, Yu HS, Ohtsuki M, Tamaki K.

J Dermatol Sci. 2013 Oct;72(1):66-8. doi: 10.1016/j.jdermsci.2013.05.005. Epub 2013 Jun 18. No abstract available.

PMID:
23876305
50.

Serum levels of angiopoietin-2, but not angiopoietin-1, are elevated in patients with erythrodermic cutaneous T-cell lymphoma.

Kawaguchi M, Sugaya M, Suga H, Miyagaki T, Ohmatsu H, Fujita H, Asano Y, Tada Y, Kadono T, Sato S.

Acta Derm Venereol. 2014 Jan;94(1):9-13. doi: 10.2340/00015555-1633.

Supplemental Content

Loading ...
Support Center